Nathaniel Craig, APRN
Family · Normal, ILNPI 1205509437
Payments from drug & device makers
Across 28 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$136
- Amgen$73
- Boehringer Ingelheim$44
- Novartis$43
- Astellas Pharma US Inc$37
- AstraZeneca$35
- plus $173 from 8 others
What the payments were for
- Food & beverage$541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $136 |
| Amgen | 4 | $73 |
| Boehringer Ingelheim | 2 | $44 |
| Novartis | 2 | $43 |
| Astellas Pharma US Inc | 2 | $37 |
| AstraZeneca | 2 | $35 |
| Novo Nordisk | 2 | $35 |
| Lundbeck LLC | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Pfizer | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$541 in reported general payments places this provider in the 60th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 14 | $16,023 |
| Donepezil Hcl | 46 | $378 |
| Memantine Hcl | 32 | $356 |
| Lisinopril | 39 | $330 |
| Pantoprazole Sodium | 16 | $256 |
| Cephalexin | 39 | $230 |
| Losartan Potassium | 22 | $183 |
| Methylprednisolone | 30 | $167 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $150 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $140 |
| Potassium Chloride | 11 | $132 |
| Omeprazole | 13 | $121 |
| Tamsulosin Hcl | 17 | $103 |
| Amlodipine Besylate | 24 | $102 |
| ClopidogrelClopidogrel Bisulfate | 17 | $92 |
Paid to pharmacies, not to this prescriber.
Other family in Normal
- Kathleen LallyNormal$14K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.